Nature Immunology 'Under Review': What Each Status Means
If your Nature Immunology submission shows Under Review, here is what Nature Portfolio editors are doing during each stage and when to follow up.
While you wait
Waiting on Nature Immunology? Get your next move ready.
The Nature Immunology wait is out of your hands; the next move isn't. Scan your next manuscript free, or run this paper through the scan to see what reviewers typically push back on, so the revision response is ready when the decision lands.
Last reviewed: 2026-10-09.
Quick answer: If your Nature Immunology submission shows "Under Review," elapsed time is the most reliable signal. Nature Immunology has a 2025 Journal Impact Factor of 26.5 in the 2026 JCR release, and reports a median of 5 days from submission to first editorial decision and 180 days from submission to acceptance (per Nature Immunology journal metrics).
Editorial decisions are made by a team of full-time professional editors at Nature Immunology, and the journal has no external editorial board involved in editorial decision-making.
Use this guide to interpret the nature immunology under review status, decide whether the wait is normal, and prepare the immunology-advance, evidence-depth, and Nature Portfolio routing package most likely to matter if reviewer reports arrive.
For a second opinion before reviewers see your manuscript, run a Nature Immunology submission readiness check.
What submission portal does Nature Immunology use?
Nature Immunology uses its own online manuscript submission and tracking system at mts-ni.nature.com. Editorial questions should reference the manuscript ID. The journal's contact page says general editorial inquiries and status inquiries can be sent to immunology@us.nature.com, and the Nature Immunology peer-review policy explains the review process.
How Nature Portfolio handles a Nature Immunology submission
Nature Immunology operates the Nature Portfolio handling editor model with a team of full-time professional editors making decisions. Unlike many specialty journals, Nature Immunology has no external editorial board involved in editorial decision-making; the professional editors make all calls.
A handling editor at Nature Immunology reads the paper and consults with the editorial team before deciding whether to send it for peer review.
Nature Portfolio editorial culture at Nature Immunology is decisive: most rejections happen at the handling editor read within days. Papers that pass the handling editor stage have cleared the steepest filter at Nature Portfolio's specialty immunology titles.
Nature Immunology's review pipeline
Status | What is happening | Journal-published timing |
|---|---|---|
Submitted | Administrative processing at Nature Portfolio editorial office | Not published |
With Editor | Handling editor evaluating desk-screen fit and broad-immunology significance | Decision to send out normally within two working days of receipt; median 5 days to first editorial decision |
Editor Team Discussion | Ambiguous papers discussed across the editorial team | Not published (invisible to author) |
Under Review | External reviewers invited or actively reviewing | Not published |
Reports Received | Handling editor synthesizing reports | Publication decisions typically within two days of receipt of the referees' reports |
Decision Sent | Reject, R&R, or accept | Check email; median 180 days from submission to acceptance |
The handling editor desk screen
Before the paper reaches external reviewers, a Nature Portfolio handling editor at Nature Immunology evaluates whether the immunology mechanism warrants Nature Immunology's selective editorial slots. The journal does not publish a desk-rejection rate, and unofficial estimates vary widely. A desk rejection most often means the handling editor concluded that the work would fit better at a sister Nature Portfolio title (Nature Communications, Communications Biology) or that the broad-immunology audience fit is uncertain.
Administrative processing
The journal's editorial assistant checks that the manuscript and associated materials are complete: the manuscript file, the cover letter and, optionally, supplementary information. If the manuscript is sent for peer review, the journal then asks for further documents, such as the Reporting Summary for life-sciences work, which recommends the ARRIVE guidelines for animal research and asks for a completed CONSORT checklist for clinical data.
What the handling editor evaluates
The handling editor reads the paper and evaluates immunology mechanism depth, broad-immunology audience fit, and the degree to which the work advances understanding of the field. Nature Portfolio guidance explicitly cites four criteria: degree of advancement, soundness of conclusions, extent of evidence supporting conclusions, and wide relevance.
Editor team discussion (parallel for ambiguous cases)
In parallel with the handling editor's primary read, ambiguous-fit papers are discussed across the Nature Immunology editorial team. This editorial-team discussion is a defining feature of Nature Immunology's decision process. The conversation runs alongside the desk-screen and is invisible to the author in the portal.
External reviewer recruitment and active peer review
Nature Portfolio handling editors at Nature Immunology typically invite two to three external reviewers. The journal does not publish a reviewer deadline or a review-stage duration; recruiting reviewers with topic-matched expertise can add time because immunology experts across subfields are in demand.
Editorial synthesis and decision
After the reports return, the primary handling editor evaluates the recommendations and comments, and the journal says decisions about publication are typically made within two days of receipt of the referees' reports.
When to worry
- Rejection within 1 to 3 days: Administrative issue or immediate scope mismatch.
- Rejection within 3 to 10 days: Handling editor desk rejection. Most rejections happen here.
- Still Under Review after 3 weeks: The journal's median time to first editorial decision is 5 days, so a manuscript still active at 3 weeks has most likely passed the desk screen and gone out for review.
- Still Under Review after 8 weeks: Likely a reviewer-recruitment or reviewer-report delay. A polite inquiry is appropriate; the journal's contact page says to write to immunology@us.nature.com about manuscript status.
- Status changes to "Reports Received": Reports are in; the journal says decisions about publication are typically made within two days of receipt of the referees' reports.
"My paper has been Under Review for 4 weeks. Is that bad?"
This is the most common anxiety we hear from Nature Immunology authors during the active editorial window. The honest answer: no, the journal's metrics page reports a median of 5 days to first editorial decision and 180 days to acceptance, so 4 weeks in review is well inside the normal range. Reviewer-driven delays often come from reviewer-recruitment timing for immunology specialists rather than slow reviews.
If the portal still says Under Review at the 6-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the handling editor granted it. This is normal practice at Nature Portfolio.
What you should NOT do during the 4-to-6-week window is email the editorial office, because an inquiry at 4 weeks adds friction without accelerating the timeline.
What to do while waiting
- Do not contact the editorial office during the first 6 weeks unless an urgent ethics issue surfaces.
- Do not submit the paper anywhere else while it is Under Review at Nature Immunology. Nature Portfolio has explicit prohibitions on dual submission.
- Prepare a point-by-point response template for likely reviewer concerns: mechanism depth, orthogonal-method validation, broad-immunology framing.
- If you have related work submitted elsewhere or recently published, prepare disclosure language for when revisions are requested.
- Read recent Nature Immunology papers in your subfield to calibrate the current editorial bar.
If Nature Immunology rejects: sister-journal cascade with reasoning
If your Nature Immunology paper is rejected after review, the natural cascade depends on what the reviewers and handling editor cited:
Nature Communications is the most natural Nature Portfolio cascade because Nature Portfolio supports manuscript transfer in which, in almost all cases, the reviewer comments are passed along to the receiving journal, preserving substantial peer-review work. Nature Communications has a broader scope and an open-access publishing model.
Communications Biology is a Nature Portfolio open-access option for technically rigorous immunology papers where the broader-immunology audience appeal is narrower than Nature Immunology's bar.
Cell Reports is a Cell Press cascade option for mechanism-focused immunology papers. Cell Press operates independently; reports do not transfer, but Cell Reports consulting editors recognize Nature Portfolio reviewer reports informally and may move quickly on resubmissions.
Immunity is a Cell Press cascade for top-mechanism immunology papers where the Cell Press transparent peer-review system is preferred.
Readiness check
While you wait on Nature Immunology, scan your next manuscript.
The scan takes about 2 to 3 minutes. Use the result to decide whether to revise before the decision comes back.
How Nature Immunology compares to nearby alternatives
Feature | Nature Immunology | Immunity | Nature Communications | Science Immunology |
|---|---|---|---|---|
Desk-rejection rate | Not published by the journal | Not published | 72.5% rejected outright (March 2015 to February 2017) | Not published |
Desk-decision speed | Median 5 days to first editorial decision (journal metrics page) | 3 to 5 business days | 3 to 14 days | 7 to 14 days |
Total review time | Median 180 days from submission to acceptance (journal metrics page) | 3 to 4 weeks | 6 to 12 weeks | 6 to 10 weeks |
Reviewer count | 2 to 3 | 2 to 3 | 2 to 3 | 2 to 3 |
Editorial team | Full-time professional editors, no external board | Cell Press consulting editors | Nature Portfolio handling editors | Science editorial team |
Editorial bar | Top immunology, broad significance | Top immunology mechanism + broad audience | Broad multidisciplinary, open access | Science-tier immunology |
Publisher-reported acceptance figures link to their source. Elsevier catalog figures were checked in October 2026; the catalog does not specify the reporting period or submission denominator.
Submit If
- Your paper has been Under Review for more than 1 week and the immunology advance is clear from the title, abstract, first figure, and cover letter.
- Your evidence package can connect mechanism, cell state, perturbation, in-vivo relevance, and human or disease context where relevant.
- Your response plan can explain why the work belongs at Nature Immunology rather than Immunity, Science Immunology, Nature Communications, Communications Biology, or Cell Reports.
If your Nature Immunology paper is Under Review past 1 week, it has most likely cleared the handling editor screen at Nature Portfolio. Use the waiting window to prepare a thorough revision response template.
Nature Immunology submission readiness check takes about 5 minutes.
Think Twice If
- The abstract is framed around one immune cell type, pathogen, tissue, or disease model without stating the broader immunology principle.
- The methods and main mechanism depend on one perturbation, one readout, or one model and the paper does not yet show independent support.
- The clinical or disease relevance is interesting, but the manuscript has not separated mechanism from association in a figure-level claim.
Nature Portfolio handling editors at Nature Immunology retain discretion to reject after partial review if reviewer reports surface mechanism-depth or broad-significance concerns the desk screen did not catch.
For a pre-upload diagnostic of mechanism depth and broad-immunology framing, run a Nature Immunology pre-submission diagnostic before reviewer reports surface those concerns.
Last verified: Nature Immunology author guidance at Nature Portfolio author guidance and Nature Portfolio editorial documentation.
The Nature Immunology reviewer experience
Nature Immunology editors weigh four criteria when deciding whether to send a paper for review, and the Nature Portfolio peer-review policy asks reviewers a broader set of questions (key results, validity, originality and significance, data and methodology, statistics, conclusions, suggested improvements, references, and clarity). The table below maps the four editorial criteria to actionable preparation.
Editorial criterion | What Nature Immunology's editors weigh | How to prepare for it |
|---|---|---|
Degree of advancement | Does the work advance understanding of the immunology field beyond incremental contribution? | Frame the introduction around the broader-immunology principle the findings illuminate. Degree of advancement is the first criterion the editors list. |
Soundness of conclusions | Are the conclusions supported by the experimental design and data quality? | Document experimental design rigorously. The Reporting Summary recommends the ARRIVE guidelines for animal work. |
Extent of evidence | Does the evidence presented support the conclusions across orthogonal methods? | Pair genetic perturbation with antibody-based readout; pair in-vitro with in-vivo phenotyping. Single-approach mechanism papers face higher reviewer skepticism. |
Wide relevance | Does the work travel beyond one immunology subfield to broader immunology audiences? | Anchor framing to broader immunology principles, so reviewers can quickly contextualize the paper. |
What we see in our pre-submission review work on Nature Immunology manuscripts
Manusights review data from this journal family shows a specific risk pattern: in practice, we see Nature Immunology editors and reviewers specifically look for whether the manuscript changes a broad immunology question, not only whether it reports a strong immune phenotype. Nature Portfolio's public guidance explains the professional-editor model and the journal's emphasis on fair and rapid review, but the author need during Under Review is more practical: identify the objections reviewers can raise.
This guide tells you what Nature Immunology editors look for during the status window. Manusights has reviewed 50+ manuscripts targeting Nature Immunology or adjacent immunology, infection, inflammation, and Nature Portfolio journals; full Manusights reviews include a 60-day money-back guarantee, and we do not train AI on customer manuscripts.
Immunology advance is framed too narrowly
We often see strong manuscripts framed around one pathogen, one cell type, one tissue niche, one cytokine axis, or one disease cohort without explaining what changes for immunology more broadly. Reviewers read quickly, so the advance needs to be visible before they reach the supplement. During Under Review, write the broad-principle sentence that connects the model-specific finding to immune differentiation, tolerance, memory, antigen presentation, innate sensing, tissue immunity, host-pathogen interaction, or immunopathology.
If that sentence is not yet clear, run a Check whether your Nature Immunology advance is broad enough ->.
Evidence package does not separate mechanism from association
Nature Immunology reviewers are wary of papers that infer mechanism from correlative single-cell data, marker shifts, cytokine readouts, or disease-cohort associations without perturbation, rescue, in-vivo relevance, or independent model support. We see the strongest packages connect phenotype, perturbation, cell-state evidence, molecular pathway, and functional consequence. If the most important claim would fail without one assay, prepare an evidence-depth map now.
Use a Check if your Nature Immunology evidence package separates mechanism from association -> for that pass.
Nature Portfolio and Cell Press routing are not settled
Nature Immunology, Immunity, Science Immunology, Nature Communications, Communications Biology, and Cell Reports reward different versions of a strong immunology story. Nature Immunology needs broad immunology advance and editor-team conviction. Immunity can fit top mechanism with Cell Press article architecture. Science Immunology rewards Science-family breadth. Nature Communications can absorb broader multidisciplinary work. Cell Reports can fit rigorous mechanism with a narrower reach.
If your paper could move across those venues without reframing, run a Check whether your Nature Immunology routing plan is defensible ->.
Nature Immunology Pre-Decision Checklist
- Write the broad immunology principle and the model-specific claim as separate sentences.
- Audit perturbation, rescue, in-vivo, human-cohort, single-cell, cytokine, flow-cytometry, and disease-context evidence before reports arrive.
- Draft likely reviewer objections around mechanism, association, model generality, and broad relevance.
- Prepare routing language for Immunity, Science Immunology, Nature Communications, Communications Biology, and Cell Reports.
Source limitations: Nature Portfolio guidance describes editorial criteria, the editor-team model, and workflow mechanics; the immunology-advance and evidence-depth guidance here is inferred from those sources plus Manusights manuscript-review patterns, not from private editorial records.
Nature Immunology external reviewer recruitment
Once the handling editor decides to send the paper for external review, Nature Immunology staff editors invite two to three reviewers (the editorial team often coordinates on borderline immunology papers), and recruitment can take time because immunology subspecialty experts across innate, adaptive, infection, and autoimmunity domains are in demand. Status updates flow through the Nature Immunology manuscript tracking system; editorial-office queries can reach immunology@us.nature.com per the Nature Immunology contact page.
Methodology note
This page was created from Nature Portfolio's public author guidance at Nature Portfolio author guidance, Nature Immunology's journal metrics and Aims & Scope pages, Nature Portfolio peer-review guidance, and Manusights pre-submission review experience with Nature Immunology-targeted manuscripts. The only timing figures taken from the journal are the medians of 5 days to first editorial decision and 180 days to acceptance, and the two-working-day norm for the decision to send a manuscript out.
What to read next
For the Nature Portfolio immunology landscape beyond Nature Immunology, see Nature Communications (broader scope with open-access), Communications Biology (Nature Portfolio open-access), Nature Reviews Immunology (review article focus), and sister Cell Press titles (Immunity, Cell Reports). The choice across these titles depends on whether the central contribution is broad-immunology-advance (Nature Immunology), broader-multidisciplinary (Nature Communications), open-access (Communications Biology), or review-article (Nature Reviews Immunology).
The journal says it works to ensure that reviewers cover the different technical and conceptual aspects of the work, so papers that reviewers can quickly contextualize against the broader literature tend to be easier to assess.
For a pre-upload check of your manuscript against the Nature Immunology broad-advancement-plus-orthogonal-validation bar before submission, our Nature Immunology pre-submission diagnostic flags the orthogonal-validation gaps and narrow-framing weaknesses most likely to surface in reviewer reports.
Frequently asked questions
Your manuscript has cleared Nature Portfolio admin checks and is being evaluated. After initial checks are complete, the manuscript is assigned to a handling editor, who reads the paper, consults with the editorial team, and decides whether it should be sent for peer review. Editors decide whether to send a manuscript for peer review based on degree to which it advances understanding of the field, soundness of conclusions, evidence supporting these conclusions, and wide relevance to the journal's readership.
The journal's metrics page reports a median of 5 days from submission to first editorial decision and 180 days from submission to acceptance, and its Aims & Scope says the decision on sending a manuscript out for peer review is normally made within two working days of receipt. Editorial decisions are made by a team of full-time professional editors at Nature Immunology.
Wait at least 8 weeks before inquiring. The journal's contact page says to write to immunology@us.nature.com to inquire about the status of your manuscript.
No. The journal's metrics page reports a median of 5 days to first editorial decision and 180 days to acceptance, so 4 weeks is well inside the normal range for a paper in review. Reviewer-driven delays often come from reviewer-recruitment timing for immunology specialists rather than slow reviews.
Your paper passed the handling editor desk screen and reviewers have been invited. Nature Immunology typically sends papers to two or three reviewers, sometimes more if special advice is needed.
Yes. The journal reports a median of 180 days from submission to acceptance, so a paper that is still in review or revision after 60 days is well within the normal range.
Past 8 weeks is the right moment for a polite inquiry. Past 12 weeks may suggest a reviewer dropped out and the handling editor needs a replacement. Silence in the first 4 weeks is normal given the journal's published medians of 5 days to first editorial decision and 180 days to acceptance.
Sources
Free guide
Waiting is not the same as being ignored, and there is a way to tell.
Reviewers usually get ten days. When it has been months, an appeal and a complaint are different instruments with different addresses, and only one of them fits a delay. This is which to use, and the wording that gets an answer.
Final step
Done interpreting the status? Put the wait to work.
The Nature Immunology decision will arrive on the journal's clock. What you control is what's next: scan your next manuscript free, or run this paper through the scan so the likely reviewer pushback is mapped before the revision request lands.
Free scan, no card needed.
Target journal Nature Immunology
Private API processing. Your manuscript is not used to train models.
Re-read the status guidePut the guidance to work
Turn a decision into a clear next step.
Use the practical response workflow when a manuscript needs revision, or the process guide when you need to understand what the editorial status means.
Where to go next
Start here
Same journal, next question
- Nature Immunology Review Time: What Authors Can Actually Expect
- Nature Immunology Submission Process
- How to Avoid Desk Rejection at Nature Immunology
- Is Nature Immunology a Good Journal? Fit Verdict
- Is Your Paper Ready for Nature Immunology? The Fundamental Discovery Test
- Nature Immunology Acceptance Rate: What Authors Can Use